- Home
- BLKB vs DNLI Comparison
BLKB vs DNLI Comparison
Compare BLKB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLKB | DNLI |
|---|---|---|
| Founded | 1981 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 2004 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BLKB | DNLI |
|---|---|---|
| Price | $62.00 | $17.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $70.50 | $32.58 |
| AVG Volume (30 Days) | 353.7K | ★ 1.7M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,136,093,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.09 | $3,993.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $54.56 | $10.57 |
| 52 Week High | $81.63 | $24.35 |
Technical Indicators
Market Signals| Indicator | BLKB | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 53.99 | 46.79 |
| Support Level | $60.62 | $17.20 |
| Resistance Level | $63.59 | $18.30 |
| Average True Range (ATR) | 1.89 | 1.03 |
| MACD | 0.55 | -0.27 |
| Stochastic Oscillator | 70.50 | 6.88 |
Price Performance
Historical ComparisonAbout BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.